Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.

By A. Menter, A. Gottlieb, S. Feldman, A. V. Van Voorhees, C. Leonardi, K. Gordon, M. Lebwohl, J. Koo, C. Elmets, N. Korman and 2 more. Journal of American Academy of Dermatology, 2008

1,339 citations recorded by the source corpus.

Subfields: Dermatology, Economics and Econometrics, Immunology

View Paper: https://www.semanticscholar.org/paper/9ea63f888926cd673b343549b84a47d5268df5b6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. C. Griffiths
2. K. Papp
3. C. Leonardi
4. K. Reich
5. R. Langley
6. N. Korman
7. A. Alikhan
8. K. Gordon

Citations in the corpus

• Hidradenitis suppurativa: a comprehensive review. (2009, background): “Upper respiratory tract infections are the most common.(196) Serious infections are uncommon, unless the patient is already predisposed because of preceding immune suppression.”
• Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). (2015, background): “In addition, apremilast demonstrated improvements in nail and scalp psoriasis, both difficult-to-treat forms of psoriasis.(15,16) Most patients rerandomized to placebo who lost PASI-75 response regained it after apremilast reinitiation.”